JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.29 -2.27

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.28

Max

1.33

Belangrijke statistieken
By Trading Economics
Inkomsten	-103K -6.6M
Werknemers	42

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+181.95% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	19M 91M
Vorige openingsprijs	3.56
Vorige sluitingsprijs	1.29

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 apr 2026, 23:47 UTC

Marktinformatie

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 apr 2026, 23:13 UTC

Acquisities, Fusies, Overnames

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 apr 2026, 22:33 UTC

Winsten

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 apr 2026, 22:17 UTC

Winsten

PLS Executed Offtake Agreement With Ronbay

23 apr 2026, 22:17 UTC

Winsten

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 apr 2026, 22:16 UTC

Winsten

PLS Commences Commissioning of Midstream Demonstration Plant

23 apr 2026, 22:15 UTC

Winsten

PLS Group Reaffirms FY26 Guidance for All Metrics

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 apr 2026, 22:13 UTC

Winsten

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 apr 2026, 22:12 UTC

Winsten

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:12 UTC

Winsten

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:11 UTC

Winsten

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 apr 2026, 22:10 UTC

Winsten

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 apr 2026, 22:09 UTC

Winsten

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 apr 2026, 22:08 UTC

Winsten

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 apr 2026, 22:04 UTC

Winsten

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 apr 2026, 21:56 UTC

Marktinformatie

Winsten

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 apr 2026, 21:27 UTC

Winsten

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 apr 2026, 21:25 UTC

Winsten

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 apr 2026, 21:24 UTC

Winsten

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 apr 2026, 21:24 UTC

Winsten

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 apr 2026, 21:21 UTC

Winsten

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 apr 2026, 21:21 UTC

Winsten

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

181.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.75 USD 181.95%

Hoogste 4 USD

Laagste 3.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.